Encompass Health Earnings Call Transcripts
Fiscal Year 2026
-
Strong growth momentum continues with expansion into new and existing markets, introduction of small-format hospitals, and robust capital allocation. Technology partnerships are driving operational efficiency, while labor and regulatory challenges are being managed effectively.
Fiscal Year 2025
-
Revenue and EBITDA grew double digits in 2025, driven by strong discharge growth, pricing, and disciplined expense management. 2026 guidance projects continued growth, with robust cash flow supporting investments and shareholder returns.
-
Q3 2025 saw 9.4% revenue and 11.4% adjusted EBITDA growth, with strong patient outcomes and labor management. Guidance was raised, capacity expansion plans accelerated, and free cash flow and share repurchases increased. Net leverage remains low and market demand is robust.
-
Q2 saw 12% revenue and 17.2% adjusted EBITDA growth, driven by strong discharge and specialty volume increases. Guidance and CapEx were raised, with robust cash flow, low leverage, and continued expansion plans supported by favorable market trends.
-
Strong volume growth continues, supported by demographic trends and high occupancy, prompting accelerated bed expansions and de novo openings. Capital deployment remains focused on high-return projects and share repurchases, while payer mix improvements and stable regulatory outlook support ongoing performance.
-
The meeting covered board elections, auditor ratification, executive compensation, and a new incentive plan, with all proposals overwhelmingly approved. No questions were submitted by stockholders during the meeting.
-
Revenue and adjusted EBITDA grew 10.6% and 14.9% year-over-year, respectively, with strong discharge growth and improved labor efficiency. Guidance for 2025 was raised, and capital is being prioritized for capacity expansion amid robust demand and favorable payer mix shifts.
-
Strong same-store discharge growth is supported by increased occupancy, bed expansions, and new facility openings. Strategic focus on clinical excellence, competitive labor practices, and capital allocation drives operational and financial performance. Medicare Advantage share and joint ventures continue to expand.
Fiscal Year 2024
-
Q4 2024 delivered double-digit revenue and EBITDA growth, with strong discharge volumes and robust expansion in key markets like Florida. 2025 guidance anticipates continued growth, increased CapEx, and ongoing focus on clinical innovation and shareholder returns.
-
Q3 2024 delivered double-digit revenue and Adjusted EBITDA growth, with broad-based discharge increases and strong payer mix performance. Guidance for 2024 was raised, reflecting robust demand, successful capacity expansion, and effective cost management.
-
Q2 2024 delivered strong revenue and EBITDA growth, driven by robust discharge increases and capacity expansion. Guidance was raised, reflecting continued demand, stable labor trends, and strategic investments, while bad debt rose due to audit activity.